130 related articles for article (PubMed ID: 15254882)
21. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
22. Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients.
Nielsen S; Jørgensen JO; Hartmund T; Nørrelund H; Nair KS; Christiansen JS; Møller N
Growth Horm IGF Res; 2002 Dec; 12(6):425-33. PubMed ID: 12423628
[TBL] [Abstract][Full Text] [Related]
23. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans.
Nuutila P; Knuuti MJ; Raitakari M; Ruotsalainen U; Teräs M; Voipio-Pulkki LM; Haaparanta M; Solin O; Wegelius U; Yki-Järvinen H
Am J Physiol; 1994 Dec; 267(6 Pt 1):E941-6. PubMed ID: 7810638
[TBL] [Abstract][Full Text] [Related]
24. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
Andreotti AC; Lanzi R; Manzoni MF; Caumo A; Moreschi A; Pontiroli AE
Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
[TBL] [Abstract][Full Text] [Related]
25. Evidence for increased liver glycogen in patients with noninsulin-dependent diabetes mellitus after a 3-day fast.
Clore JN; Post EP; Bailey DJ; Nestler JE; Blackard WG
J Clin Endocrinol Metab; 1992 Mar; 74(3):660-6. PubMed ID: 1740502
[TBL] [Abstract][Full Text] [Related]
26. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
27. Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man.
Ekstrand A; Saloranta C; Ahonen J; Grönhagen-Riska C; Groop LC
Metabolism; 1992 Jul; 41(7):692-7. PubMed ID: 1619986
[TBL] [Abstract][Full Text] [Related]
28. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity.
Wang XX; Ye T; Li M; Li X; Qiang O; Tang CW; Liu R
Mol Med Rep; 2017 Jul; 16(1):109-118. PubMed ID: 28534956
[TBL] [Abstract][Full Text] [Related]
29. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
Fulcher GR; Walker M; Farrer M; Johnson AS; Alberti KG
Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycemia or total hepatic glucose production in NIDDM.
Puhakainen I; Yki-Järvinen H
Diabetes; 1993 Dec; 42(12):1694-9. PubMed ID: 8243814
[TBL] [Abstract][Full Text] [Related]
31. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
32. Acute regulation of adiponectin by free fatty acids.
Bernstein EL; Koutkia P; Ljungquist K; Breu J; Canavan B; Grinspoon S
Metabolism; 2004 Jun; 53(6):790-3. PubMed ID: 15164330
[TBL] [Abstract][Full Text] [Related]
33. Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs.
Chu CA; Sherck SM; Igawa K; Sindelar DK; Neal DW; Emshwiller M; Cherrington AD
Am J Physiol Endocrinol Metab; 2002 Feb; 282(2):E402-11. PubMed ID: 11788373
[TBL] [Abstract][Full Text] [Related]
34. Metabolic effect of decreasing nonesterified fatty acid levels with acipimox in hyperthyroid patients.
Park KS; Kim CH; Lee MK; Shin CS; Park DJ; Kim SY; Cho BY; Lee HK
Metabolism; 1999 Oct; 48(10):1318-21. PubMed ID: 10535397
[TBL] [Abstract][Full Text] [Related]
35. Assessment of postprandial hepatic glycogen synthesis from uridine diphosphoglucose kinetics in obese and lean non-diabetic subjects.
Paquot N; Schneiter P; Scheen AJ; Lefèbvre PJ; Tappy L
Int J Obes Relat Metab Disord; 2000 Oct; 24(10):1297-302. PubMed ID: 11093291
[TBL] [Abstract][Full Text] [Related]
36. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Pontiroli AE; Lanzi R; Monti LD; Pozza G
J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
[TBL] [Abstract][Full Text] [Related]
37. Enhanced circadian ACTH release in obese premenopausal women: reversal by short-term acipimox treatment.
Kok P; Kok SW; Buijs MM; Westenberg JJ; Roelfsema F; Frölich M; Stokkel MP; Meinders AE; Pijl H
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E848-56. PubMed ID: 15280154
[TBL] [Abstract][Full Text] [Related]
38. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes.
Boden G; Chen X; Capulong E; Mozzoli M
Diabetes; 2001 Apr; 50(4):810-6. PubMed ID: 11289046
[TBL] [Abstract][Full Text] [Related]
39. Acipimox enhances spontaneous growth hormone secretion in obese women.
Kok P; Buijs MM; Kok SW; Van Ierssel IH; Frölich M; Roelfsema F; Voshol PJ; Meinders AE; Pijl H
Am J Physiol Regul Integr Comp Physiol; 2004 Apr; 286(4):R693-8. PubMed ID: 14670810
[TBL] [Abstract][Full Text] [Related]
40. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans.
Fanelli C; Calderone S; Epifano L; De Vincenzo A; Modarelli F; Pampanelli S; Perriello G; De Feo P; Brunetti P; Gerich JE
J Clin Invest; 1993 Oct; 92(4):1617-22. PubMed ID: 8408616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
